GlobeNewsWire
08 Jan 2026, 21:05 UTC · 44w ago
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
Impact · against what's priced in
The abandonment of the Re-Tain pipeline due to FDA regulatory failures is a significant negative catalyst that outweighs modest top-line growth. While expansion of the sales force and improved operational efficiency provide some support, the $3.6 million in total write-downs and the loss of a growth asset create a net negative outlook.
- ICCC−0.20
No priced-in read yet





